Acute onset of pancreatitis with concomitant use of tenofovir and didanosine

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1660-1663

  Kirian, Margaret A ^a   Higginson, Robert T ^b   Fulco, Patricia Pecora ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Didanosine; Pancreatitis; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG MECHANISM; FATTY LIVER; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MALE; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY;

ACUTE DISEASE; ADENINE; ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PHOSPHONIC ACIDS;

EID: 4644357377     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D616     Document Type: Article

References (24)

1. Package insert. Viread (tenofovir DF). Foster City, CA: Gilead Sciences, October 2003.
2. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
3. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
4. Staazewski S, Gallant JE, Pozniak AL, Suleiman JMAH, DeJesus E, Sayre J, et al. Efficacy and safety of tenofovir DF vs. stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results (poster 564b). Presented at: 10th Conference of Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003.
5. Department of Health and Human Services, the Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.aidsinfo.nih.gov (accessed 2004 Apr 27).
6. Kearney BP, Flaherty J, Wolf J, Barriere S, Wong S, Chen SS, et al. Coadministration of tenofovir DF and didanosine: a pharmacokinetic and safety evaluation (poster 172). Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 28-31, 2001.
7. Kearney BP, Damle B, Plummer A, Sayre J, Namini H, Ryan K, et al. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine (poster 9026). Presented at: 14th International AIDS Conference, Barcelona, July 7-12, 2002.
8. Package insert. Videx EC (didanosine). Princeton, NJ: Bristol-Myers Squibb, January 2002.
9. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, et al. Long-term toxicity/activity profile of 2′,3′dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526-9.
10. Blanchard JN, Wohlfeiler M, Canas A, King K, Longeran JT. Pancreatitis treated with didanosine and tenofovir disoproxil fumarate. Clin Infect Dis 2003;37:e57-62.
11. Davies L, Yoganathan K. Fatal acute pancreatitis in an HIV-positive man-the result of an interaction between tenofovir disoproxil fumarate (TDF) and didanosine (ddI) (P124). Presented at: Sixth International Congress on Drug Therapy in HIV Infection, Glascow, November 17-21, 2002.
12. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003;36:1082-5.
13. Rivas P, Polo J, de Gorgolas M, Fernandez-Guerrero ML. Fatal lactic acidosis associated with tenofovir (letter). BMJ 2003;327:711.
14. Callens S, de Schacht C, Huyst V, Colebunders R. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment. J Infect 2003;47:188-9.
15. Rollot F, Nazal EM, Chauvelot-Moachon L, Kelaidi C, Daniel N, Saba M, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-6.
16. DeChristoforo R, Penzak SR. Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004;61:86-100.
17. Kearney BP, Isaacson E, Sayre J, Plummer A, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction (poster 533). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003.
18. Food and Drug Administration. PDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women (talk paper T01-02). Rockville, MD: US Department of Health and Human Services, January 5, 2001.
19. Raffi F, Saag M, Cahn P, Wolff M, Pearce D, Molina JM, et al. A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID in treatment-naïve HIV-infected patients. Presented at: 2nd IAS Conference on Pathogenesis and Treatment, Paris, July 13-16, 2003.
20. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003;17:2045-52.
21. Barrios A, Negredo E, Vilaro-Rodriguez J, Domingo P, Estrada V, Labarga P, et al. Safety and efficacy of a QD simplification regimen (poster 566). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
22. Martinez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004;364:65-7.
23. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
24. Pecora Fulco P, Kirian M. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003;37:1325-8. DOI 10.1345/aph.1C412